Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
An In-depth Analysis of Milrinone Lactate's R&D Progress and Mechanism of Action on Drug Target
19 September 2023
This article summarized the latest R&D progress of Milrinone Lactate, the Mechanism of Action for Milrinone Lactate, and the drug target R&D trends for Milrinone Lactate.
Valuable Targets
6 min read
LSD1 inhibitors - A potent inhibitory target for tumor immunotherapy
19 September 2023
LSD1, also known as lysine-specific demethylase 1A, is an enzyme that plays a crucial role in the regulation of gene expression in the human body.
Drug Insights
4 min read
Midazolam Hydrochloride: Detailed Review of its Transformative R&D Success
19 September 2023
This article summarized the latest R&D progress of Midazolam Hydrochloride, the Mechanism of Action for Midazolam Hydrochloride, and the drug target R&D trends for Midazolam Hydrochloride.
Latest Hotspot
3 min read
Exelixis and Insilico Medicine Enter into an exclusive global licensing deal for ISM3091
19 September 2023
Insilico Medicine and Exelixis, Inc. announced a licensing agreement allowing Exelixis to globally produce and market ISM3091, a promising USP1 inhibitor related to BRCA-altered cancers.
Drug Insights
4 min read
Deep Scientific Insights on Metreleptin's R&D Progress, Mechanism of Action
19 September 2023
This article summarized the latest R&D progress of Metreleptin, the Mechanism of Action for Metreleptin, and the drug target R&D trends for Metreleptin.
Valuable Targets
5 min read
Allergy Terminator: Leukotriene Receptor Antagonist
19 September 2023
Leukotriene antagonists work by blocking the action of leukotrienes, they are mainly used for preventing asthma, controlling allergic rhinitis or allergic reactions.
Drug Insights
4 min read
An In-depth Analysis of Lonafarnib's R&D Progress and Mechanism of Action on Drug Target
19 September 2023
This article summarized the latest R&D progress of Lonafarnib, the Mechanism of Action for Lonafarnib, and the drug target R&D trends for Lonafarnib.
Latest Hotspot
4 min read
BioLineRx reveals FDA approval for APHEXDA™ (motixafortide) to stimulate stem cell collection for autologous transplant in Multiple Myeloma patients
19 September 2023
BioLineRx Discloses FDA Authorization for APHEXDA™ (motixafortide), to Activate Hematopoietic Stem Cells for Gathering and Subsequent Autologous Transplantation in Multiple Myeloma Patients.
Drug Insights
4 min read
Ixabepilone: Detailed Review of its Transformative R&D Success
19 September 2023
This article summarized the latest R&D progress of Ixabepilone, the Mechanism of Action for Ixabepilone, and the drug target R&D trends for Ixabepilone.
Valuable Targets
6 min read
Another Potential Stock after PD1 - LAG3 Inhibitors
19 September 2023
The Lymphocyte-activation gene-3 (LAG-3) is located on human chromosome 12 (20p13.3), includes 8 exons, and its corresponding cDNA encodes a membrane protein containing 498 amino acids.
Drug Insights
4 min read
Fosaprepitant Dimeglumine Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Fosaprepitant Dimeglumine, the Mechanism of Action for Fosaprepitant Dimeglumine, and the drug target R&D trends for Fosaprepitant Dimeglumine.
Latest Hotspot
4 min read
Takeda Reveals Promising Initial Findings from Phase 2b Trial Examining TAK-279, aimed at treatment of Active Psoriatic Arthritis
19 September 2023
Takeda has shared positive initial results from its Phase 2b trial, on TAK-279, a selective, orally administered TYK2 inhibitor, which is assessed for its efficacy in treating active psoriatic arthritis.